| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 12.64M | 12.62M | 51.90M | 49.64M | 12.11M | 69.77M | 
| Gross Profit | -30.79M | -31.86M | 5.62M | 6.01M | -34.89M | 20.07M | 
| EBITDA | -48.11M | -50.99M | -1.84M | -61.30M | -43.23M | 13.30M | 
| Net Income | -46.05M | -49.47M | -7.57M | -58.10M | -52.81M | -63.98M | 
| Balance Sheet | ||||||
| Total Assets | 92.94M | 111.06M | 184.19M | 207.86M | 267.50M | 307.42M | 
| Cash, Cash Equivalents and Short-Term Investments | 60.03M | 80.77M | 92.46M | 101.48M | 119.84M | 151.64M | 
| Total Debt | 27.03M | 31.00M | 39.89M | 42.25M | 44.25M | 19.09M | 
| Total Liabilities | 87.79M | 102.22M | 132.29M | 153.71M | 160.06M | 151.45M | 
| Stockholders Equity | 5.14M | 8.83M | 51.90M | 54.15M | 107.44M | 155.97M | 
| Cash Flow | ||||||
| Free Cash Flow | -41.26M | -7.29M | -34.91M | -20.28M | -59.79M | -63.09M | 
| Operating Cash Flow | -41.10M | -6.90M | -32.56M | -19.15M | -58.46M | -51.81M | 
| Investing Cash Flow | 15.24M | 9.20M | 20.63M | 1.88M | -917.00K | -13.37M | 
| Financing Cash Flow | 8.79M | -6.01M | -1.97M | -1.83M | 26.82M | -1.14M | 
Innate Pharma announced it will host an analyst and investor event on October 28, 2025, focusing on its lead product, lacutamab, which is progressing towards potential accelerated approval in Sézary syndrome (SS) and the initiation of a confirmatory Phase 3 trial. The event will feature insights from T-cell lymphoma expert Dr. Pierluigi Porcu on the Phase 2 TELLOMAK trial results and market analysis from ZS Associates. Innate Pharma’s management will discuss the regulatory pathway and commercial opportunities for lacutamab, highlighting its potential to improve outcomes for patients with cutaneous T-cell lymphoma (CTCL) and create value for shareholders.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapy treatments against cancer, leveraging the innate immune system through monoclonal antibodies, NK Cell Engagers, and antibody-drug conjugates. Based in Marseille, France, it is publicly traded on Euronext Paris and Nasdaq.
In the recent earnings call, Innate Pharma S.A. conveyed a strategic pivot towards prioritizing high-value clinical assets, reflecting a positive outlook for future growth. The sentiment was largely optimistic, focusing on promising progress in key trials. However, there were underlying concerns regarding reduced R&D spending and the departure of a key scientific leader, which could impact future innovation. Despite these challenges, the company maintains a stable financial position, supporting its strategic objectives.
Innate Pharma SA reported its first half 2025 business update and financial results, highlighting significant progress in its clinical pipeline. The company is advancing its IPH4502 Nectin-4 ADC through Phase 1 trials and preparing for a Phase 3 trial of lacutamab following its FDA Breakthrough Therapy Designation. Strategic priorities include focusing on high-value clinical assets and streamlining operations, with a planned 30% reduction in staffing. A €15 million equity investment by Sanofi and a strong cash position of €70.4 million as of June 30, 2025, support Innate’s continued development efforts.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
On September 16, 2025, Innate Pharma SA’s Board of Directors approved the interim condensed consolidated financial statements for the first half of 2025, which were subsequently reviewed by the company’s statutory auditors. The report highlights the company’s ongoing efforts in developing its portfolio of drug candidates, including ANKET® and IPH4502, aimed at treating multiple tumor types. This financial update provides stakeholders with insights into Innate Pharma’s current financial health and strategic direction in the competitive biotechnology industry.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
Innate Pharma announced its participation in the 25th European Midcap Event from September 30 to October 1, 2025, in Paris, France. This event is significant for fostering strategic meetings and financing opportunities, potentially impacting Innate Pharma’s industry positioning and stakeholder engagement.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
Innate Pharma S.A. announced a conference call and webcast scheduled for September 17, 2025, to discuss its financial results and business updates for the first half of 2025. The event will feature key executives, including CEO Jonathan Dickinson, and will provide insights into the company’s progress and strategic initiatives. This announcement is significant for stakeholders as it reflects Innate Pharma’s ongoing commitment to transparency and engagement with investors, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
On September 2, 2025, Innate Pharma S.A. announced its total number of shares and voting rights as of September 1, 2025. The company reported 92,185,473 ordinary shares, 6,419 Preferred Shares 2016, and 7,581 Preferred Shares 2017, with a total of 93,962,943 theoretical voting rights and 93,944,368 exercisable voting rights. This update ensures market transparency and informs stakeholders about the company’s current shareholding structure.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
On August 4, 2025, Innate Pharma S.A. released its total number of shares and voting rights as of August 1, 2025, as part of its regulatory obligations under French and AMF regulations. The company reported 92,184,823 ordinary shares, 6,424 Preferred Shares 2016, and 7,581 Preferred Shares 2017, with a total of 93,962,943 theoretical voting rights and 93,944,368 exercisable voting rights. This disclosure ensures transparency and informs the market about the company’s shareholding structure, which is crucial for stakeholders and potential investors.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.